Therapy Areas: Oncology
IDEAYA Biosciences nominates IDE101 as development candidate, targeting CDKN2A-deficiency in solid tumours
16 November 2026 -

Precision medicine oncology company IDEAYA Biosciences Inc (Nasdaq:IDYA) on Sunday announced the development candidate nomination of IDE101, a potential first-in-class dual cyclin-dependent kinase (CDK) inhibitor designed to address the loss of CDKN2A-mediated tumour suppressor function in cancer.

CDKN2A-deficiency occurs in approximately 10-15% of all solid tumours, including around 70% of pancreatic ductal adenocarcinoma (PDAC), and is typically co-deleted in methylthioadenosine phosphorylase (MTAP)-deficient cancers given their proximity on chromosome 9p21.

IDEAYA says that IDE101 was discovered through its iterative physics-based ligand design and optimisation platform, and is a highly potent and selective dual CDK inhibitor with first-in-class potential and favourable drug-like properties. IND-enabling studies for IDE101 are ongoing to support an Investigational New Drug (IND) filing to the US Food and Drug Administration (FDA) in the first half of 2027, subject to satisfactory completion of ongoing preclinical and IND-enabling studies.

Login
Username:

Password: